SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
SciSparc (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) have announced the publication of an international patent application for a pioneering Ibogaine combination therapy. This innovative treatment aims to enhance safety and efficacy in mental health and addiction care. The patent application, filed under the Patent Cooperation Treaty, covers the combination of Ibogaine with N-Acylethanolamines.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown potential in treating various substance use disorders. The collaboration between SciSparc and Clearmind focuses on developing therapies that combine psychedelic molecules with N-acylethanolamines, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind in the U.S. and other global jurisdictions.
SciSparc (Nasdaq: SPRC) e Clearmind Medicine Inc. (Nasdaq: CMND) hanno annunciato la pubblicazione di una domanda di brevetto internazionale per una terapia combinata a base di Ibogaine all'avanguardia. Questo trattamento innovativo mira a migliorare la sicurezza e l'efficacia nella cura della salute mentale e delle dipendenze. La domanda di brevetto, presentata ai sensi del Trattato di cooperazione in materia di brevetti, copre la combinazione di Ibogaine con N-Acilethanolamine.
L'Ibogaine, derivato dall'arbusto Tabernanthe iboga, ha mostrato potenziale nel trattamento di vari disturbi legati all'uso di sostanze. La collaborazione tra SciSparc e Clearmind si concentra sullo sviluppo di terapie che combinano molecole psichedeliche con N-acilethanolamine, inclusa la Palmitoiletanolamide. A oggi, sono stati depositati tredici brevetti relativi a questa collaborazione da Clearmind negli Stati Uniti e in altre giurisdizioni globali.
SciSparc (Nasdaq: SPRC) y Clearmind Medicine Inc. (Nasdaq: CMND) han anunciado la publicación de una solicitud de patente internacional para una terapia combinada de Ibogaína pionera. Este tratamiento innovador tiene como objetivo mejorar la seguridad y eficacia en el cuidado de la salud mental y de las adicciones. La solicitud de patente, presentada bajo el Tratado de Cooperación en Materia de Patentes, cubre la combinación de Ibogaína con N-Acilethanolaminas.
La Ibogaína, derivada del arbusto Tabernanthe iboga, ha mostrado potencial en el tratamiento de varios trastornos por uso de sustancias. La colaboración entre SciSparc y Clearmind se centra en desarrollar terapias que combinan moléculas psicodélicas con N-acilethanolaminas, incluida la Palmitoiletanolamina. Hasta la fecha, se han presentado trece patentes relacionadas con esta colaboración por Clearmind en EE.UU. y otras jurisdicciones globales.
SciSparc (나스닥: SPRC)와 Clearmind Medicine Inc. (나스닥: CMND)는 혁신적인 이보가인 복합요법에 대한 국제 특허 출원을 발표했습니다. 이 혁신적인 치료법은 정신 건강 및 중독 치료의 안전성과 효능을 향상시키는 것을 목표로 합니다. 특허 출원은 특허 협력 조약에 따라 제출되었으며, 이보가인을 N-아실에탄올아민과 결합한 내용을 포함합니다.
이보가인은 타베르난테 이보가 관목에서 유래하며, 다양한 물질 사용 장애 치료에 잠재력을 보였습니다. SciSparc와 Clearmind 간의 협력은 N-아실에탄올아민과 함께 환각 분자를 결합한 치료법 개발에 중점을 두고 있으며, 여기에는 팔미토일에탄올아민이 포함됩니다. 현재까지 Clearmind는 미국 및 기타 글로벌 관할권에 대해 이 협력과 관련된 13개의 특허를 출원했습니다.
SciSparc (Nasdaq: SPRC) et Clearmind Medicine Inc. (Nasdaq: CMND) ont annoncé la publication d'une demande de brevet international pour une thérapie combinée à base d'Ibogaïne innovante. Ce traitement novateur vise à améliorer la sécurité et l'efficacité dans le domaine de la santé mentale et des soins liés à la dépendance. La demande de brevet, déposée selon le Traité de coopération en matière de brevets, couvre la combinaison de l'Ibogaïne avec des N-Acylethanolamines.
L'Ibogaïne, dérivée de l'arbuste Tabernanthe iboga, a montré un potentiel dans le traitement de divers troubles liés à la consommation de substances. La collaboration entre SciSparc et Clearmind se concentre sur le développement de thérapies qui combinent des molécules psychédéliques avec des N-Acylethanolamines, y compris le Palmitoïléthanolamide. À ce jour, treize brevets liés à cette collaboration ont été déposés par Clearmind aux États-Unis et dans d'autres juridictions mondiales.
SciSparc (Nasdaq: SPRC) und Clearmind Medicine Inc. (Nasdaq: CMND) haben die Veröffentlichung eines internationalen Patentantrags für eine bahnbrechende Ibogaine-Kombinationstherapie angekündigt. Diese innovative Behandlung zielt darauf ab, die Sicherheit und Wirksamkeit in der Psychischen Gesundheits- und Suchtbehandlung zu verbessern. Der Patentantrag, der im Rahmen des Patentzusammenarbeitsvertrags eingereicht wurde, umfasst die Kombination von Ibogaine mit N-Acylethanolaminen.
Ibogaine, das aus dem Tabernanthe iboga Strauch stammt, hat sich als potenziell wirksam bei der Behandlung verschiedener Substanzgebrauchsstörungen erwiesen. Die Zusammenarbeit zwischen SciSparc und Clearmind konzentriert sich auf die Entwicklung von Therapien, die psychedelische Moleküle mit N-Acylethanolaminen kombinieren, einschließlich Palmitoylethanolamid. Bis heute wurden dreizehn Patente im Zusammenhang mit dieser Zusammenarbeit von Clearmind in den USA und anderen globalen Jurisdiktionen eingereicht.
- Publication of an international patent application for a novel Ibogaine combination therapy
- Potential for improved safety and efficacy in mental health and addiction treatment
- Thirteen patents filed related to the collaboration in multiple jurisdictions
- None.
This patent application for combining Ibogaine with N-Acylethanolamines represents a significant step forward in addiction treatment research. Ibogaine's potential in treating substance use disorders is well-documented, but its use has been due to safety concerns. The addition of N-Acylethanolamines, particularly Palmitoylethanolamide, could potentially enhance efficacy while mitigating risks.
The collaboration between SciSparc and Clearmind demonstrates a strategic approach to drug development, leveraging the strengths of both companies. With thirteen patents already filed, this indicates a robust pipeline and potential for multiple revenue streams if successful. However, investors should note that the path to FDA approval for psychedelic-based therapies is still uncertain and could face regulatory hurdles.
The international patent application under the Patent Cooperation Treaty is a strategic move to secure global intellectual property rights. This approach allows SciSparc and Clearmind to protect their innovation in multiple jurisdictions simultaneously, potentially creating significant barriers to entry for competitors.
However, investors should be aware that patent applications don't guarantee approval. The novelty and non-obviousness of the combination therapy will be scrutinized. Additionally, as this involves a naturally occurring substance (Ibogaine), there may be challenges in patenting certain aspects of the therapy. The companies' ability to navigate these complex IP landscapes will be important for long-term value creation.
While this news doesn't directly impact current financials, it strengthens SciSparc's and Clearmind's long-term potential. The patent application represents a valuable intangible asset that could translate into future revenue streams through licensing or direct commercialization. However, investors should note that drug development is a lengthy and costly process with no guaranteed returns.
The collaboration allows for risk sharing and resource pooling, which is financially prudent in the high-stakes pharmaceutical industry. With multiple patents filed, the companies are building a diverse portfolio of potential treatments, which could mitigate risk if any single application fails. Investors should monitor the progress of clinical trials and regulatory approvals as key milestones for assessing the future financial impact of this intellectual property.
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care
TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of an international patent application under the Patent Cooperation Treaty for the innovative combination of Ibogaine with N-Acylethanolamines.
Ibogaine is the major constituent of the root of Tabernanthe iboga, a shrub commonly found in Western and Central Africa. Ibogaine use in human clinical trials suggests efficacy in the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders, suggesting that Ibogaine is a potentially useful anti-addictive agent.
Under this collaboration, the SciSparc and Clearmind are researching innovative combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing ongoing collaborative research with Clearmind and potential benefits and advantages of Ibogaine. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the focus of SciSparc and Clearmind's new patent application?
How many patents has Clearmind filed related to the collaboration with SciSparc (SPRC)?
What potential benefits does Ibogaine offer in medical treatment according to SciSparc's announcement?
What is the main compound being combined with Ibogaine in SciSparc (SPRC) and Clearmind's research?
